PATENT CLAIM ANALYSIS

Application Number: 15993267
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-12
Patent Classification: ["514", "04400A"]

Abstract:
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.

Claim (Index 1):
An antisense oligomer of Formula (V): or a pharmaceutically acceptable salt thereof, wherein: each Nu is a nucleobase which taken together form a targeting sequence; and T is a moiety selected from: R 1  is C 1 -C 6  alkyl; and R 2  is selected from H or acetyl, wherein the targeting sequence is complementary to an exon 52 annealing site in the dystrophin pre-mRNA designated as H52A(\u221201+24); and wherein the targeting sequence is SEQ ID NO: 1 (5\u2032-CTGTTCCAAATCCTGCATTGTTGCC-3\u2032), wherein each thymine (T) is optionally uracil (U).

Metadata:
- Claim Count in Document: 47.0
- Percentile: 93.0
- Lexical Diversity: 1.05
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13219401', '14240832', '15339069', '14368307', '15735094']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7886565084553213
- 35 USC 102 Novelty (BERT): 0.5554755201968605
- Combined Prediction Score: 0.7653384096294753
- Mean Citation Score: 384.060624
- Max Citation Score: 422.58295
- Similarity Product: 292.30182779679296

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test